Table 4.
Univariate analysis for relapse, OS, LFS, and GRFS.
| Variable | To CIR | To OS | To LFS | To GRFS |
|---|---|---|---|---|
| P value | P value | P value | P value | |
| Age (≤40 years/>40 years) | 0.996 | 0.889 | 0.683 | 0.993 |
| Sex (male/female) | 0.697 | 0.679 | 0.742 | 0.163 |
| Risk stratification (intermediate/high) | 0.009 | 0.019 | 0.01 | 0.012 |
| Disease status before HSCT (CRMRD-/CRMRD+/NR) | 0.478 | 0.043 | 0.106 | 0.132 |
| Disease course before HSCT (≤12 months/>12 months) | 0.452 | 0.36 | 0.343 | 0.876 |
| Donor/recipient sex match (female-male/others) | 0.029 | 0.186 | 0.103 | 0.291 |
| Donor HLA type(HLA-identical sibling/HLA-antigen mismatched related) | 0.698 | 0.522 | 0.527 | 0.209 |
| Stem cell source (PBSC/PBSC+BM) | 0.819 | 0.731 | 0.923 | 0.612 |
| Conditioning regimen (Dec/mBuCy) | 0.13 | 0.031 | 0.016 | 0.043 |
| aGVHD grades II–IV | 0.237 | 0.921 | 0.889 | |
| aGVHD grades III–IV | 0.75 | 0.748 | 0.802 | |
| cGVHD | 0.924 | 0.634 | 0.686 | |
| Limited cGVHD | 0.866 | 0.375 | 0.415 | |
| Extensive cGVHD | 0.766 | 0.142 | 0.174 |
CIR, cumulative incidence of relapse; OS, overall survival; LFS, leukemia-free survival; GRFS, graft-versus-host disease-free relapse-free survival; HSCT, hematopoietic stem cell transplantation; CR, complete remission; MRD, minimal residual disease; NR, active disease; PBSC, peripheral blood stem cell; BM, bone marrow; Dec, decitabine; mBuCy, modified busulfan/cyclophosphamide; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.